Skip to content

Migraine CGRP monoclonal antibody observational study

CGRP monoclonal antibodies (mAbs) have been effective for many migraine patients who previously failed the standard treatments. The purpose of this research study is to assess early results of all four currently available CGRP mAbs (fremanezumab, galcanezumab, erenumab and eptinezumab), with the focus on their tolerability and safety. Also, this study will try to answer the important question of whether non-responders to treatment with one of the CGRP mAbs benefit from switch to another other Ab or not.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    18 to 90

Critères de participation

Inclusion Criteria:
1. 18 years of age or older.
2. Have a diagnosis of migraines, with four or more migraine days per month.
3. Have received one of the following mentioned treatments for at least one month: galcanezumab 240 mg, galcanezumab 120 mg, erenumab 140 mg, erenumab 70 mg, fremanezumab 675 mg, fremanezumab 225 mg, eptinezumab 100 mg IV or eptinezumab 300 mg IV.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB22-1075